Document Detail


Valsartan and the kidney: review of preclinical and clinical data.
MedLine Citation:
PMID:  11446269     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In both diabetic and nondiabetic renal disease, reducing blood pressure with antihypertensive therapy has beneficial effects on renal function. The key role of the renin-angiotensin system in blood pressure and volume homeostasis has long been established, but its importance for the overall normal functioning of the kidney itself is also increasingly being recognized. Angiotensin-converting enzyme (ACE) inhibitors, widely and successfully used in the treatment of hypertension, may also provide renal protection independent of blood pressure reduction; however, their relatively nonspecific mode of action in blocking an early metabolic step entails major clinical disadvantages, such as accumulation of bradykinin and substance P, that may cause the characteristic ACE-inhibitor side effects of persistent dry cough and, more rarely, angioneurotic edema. Angiotensin II antagonists or receptor blockers, a new class of antihypertensive agent, selectively antagonize the AT1 receptor subtype and, because of greater specificity, do not give rise to the side effects associated with ACE inhibitors. More important, these new drugs may have mechanistic advantages over other antihypertensives, including ACE inhibitors.
Authors:
L M Ruilope
Related Documents :
6229379 - Reversal of left ventricular hypertrophy with captopril: heterogeneity of response amon...
10622089 - Angiotensin ii type 1 receptor blockade: a new development in cardiovascular pharmacology.
3415779 - Enhanced brachial artery compliance following perindopril in essential hypertension.
8146829 - Cart and logistic regression analyses of risk factors for first dose hypotension by an ...
2651329 - The effect of the first dose of captopril on blood pressure in infants in heart failure.
6277579 - Etiopathogenesis of excess methylprednisolone arterial hypertension in the rat.
25294299 - Beetroot supplementation lowers daily systolic blood pressure in older, overweight subj...
19643769 - Impact of continuous positive airway pressure treatment on left atrial volume and funct...
20208399 - Trends in body mass index, blood pressure, and serum lipids in japanese children: iwata...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Advances in therapy     Volume:  18     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:    2001 Mar-Apr
Date Detail:
Created Date:  2001-07-11     Completed Date:  2001-08-16     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  57-66     Citation Subset:  T    
Affiliation:
Hospital 12 de Octubre, Nephrology Service, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / pharmacology
Animals
Antihypertensive Agents / pharmacology*,  therapeutic use
Blood Pressure / drug effects
Diabetic Nephropathies / drug therapy,  physiopathology
Humans
Hypertension / drug therapy,  physiopathology
Kidney / drug effects*,  physiology,  physiopathology
Kidney Diseases / drug therapy,  physiopathology
Receptors, Angiotensin / antagonists & inhibitors*
Tetrazoles / pharmacology*,  therapeutic use
Valine / analogs & derivatives*,  pharmacology*,  therapeutic use
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Receptors, Angiotensin; 0/Tetrazoles; 137862-53-4/valsartan; 7004-03-7/Valine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lesions as therapy: rigidity and Parkinson's disease.
Next Document:  Intensive postremission chemotherapy in Taiwanese adults with acute myelogenous leukemia.